On October 23, 2014, the Minister of National Revenue (the Minister) filed Notices of Application in the Federal Court against a number of generic drug manufacturers, including Actavis Pharma Company, Apotex Inc., Mylan Pharmaceuticals ULC, Pharmaceutical Partners of Canada Inc., Pharmascience Inc., Ranbaxy Pharmaceuticals Canada Inc., Sandoz Canada Inc., Taro Pharmaceuticals, and Teva Canada Limited1 (the Respondents), to authorize the Minister to require the Respondents to provide information on rebates and other incentives paid to pharmacies and pharmacists.


The Notices of Application state that in the course of an audit of an unidentified pharmaceutical company in Canada, the Canada Revenue Agency discovered that pharmaceutical companies were paying rebates, incentive payments, professional allowances, promotional allowances, fees for service or other payments (referred to collectively in the Notices of Application as Incentive Payments) to pharmacies and pharmacists who were not reporting such Incentive Payments for tax purposes.

Under the Income Tax Act (Canada) (the ITA) the Minister (through the Canada Revenue Agency (CRA)) can require any person to provide documents or information for any purpose related to the administration or enforcement of the ITA. However, when the information sought relates to unnamed persons  such requirement cannot be imposed without judicial authorization.

As the CRA intends to require the Respondents to identify the pharmacies and pharmacists who received Incentive Payments and the nature of the payments received the Applications are brought pursuant to section 231.2(3) of the ITA to obtain judicial authorization to require the Respondents to provide the requested information. CRA has limited the authorization to Incentive Payments made from January 1, 2010 to December 31, 2012 to pharmacies and pharmacists located in Canada.

The Respondents may oppose the Applications. If the Applications are granted, the CRA will issue the Respondents a formal “Requirement to Provide Information”. The Respondents will then be required to provide the information within the time stipulated in the Requirement.


1  Actavis Pharma Company (T-2183-14), Apotex Inc. (T-2182-14), Mylan Pharmaceuticals ULC (T-2181-14), Pharmaceutical Partners of Canada Inc. (T-2179-14), Pharmascience Inc. (T-2178-14), Ranbaxy Pharmaceuticals Canada Inc. (T-2177-14), Sandoz Canada Inc. (T-2176-14), Taro Pharmaceuticals Inc. (T-2174-14), and Teva Canada Limited (T-2173-14).

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world’s pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members (‘the Norton Rose Fulbright members’) of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.